PubMed Mihovilovic, K., Sever, M., Zoricic, I., et al
A., Seljeflot, I., & Hanssen, K
The complete list of substances being removed from Category 2 is as follows: BPC-157 Cathelicidin LL-37 Dihexa Acetate Emideltide (DSIP) Epitalon GHK-Cu (for injectable routes of administration) KPV Mechano Growth Factor, Pegylated (PEG-MGF) Melanotan II MOTs-C Semax (heptapeptide) Thymosin Beta-4, Fragment (LKKTETQ) (TB-500) Of these, the substances not scheduled for consideration at the upcoming meeting in July (Cathelicidin LL-37, Dihexa Acetate, GHK-Cu (injectable routes of administration), Mechano Growth Factor Pegylated (PEG-MGF), and Melanotan II) are slated for separate PCAC consultation before the end of February 2027
I felt comfortable through the whole process
The smaller 10mL multi-use vial format is well suited for laboratory settings requiring precise measurement, reduced material waste, and controlled peptide preparation procedures
B12 testing is recommended in patients with fatty liver disease who have: Symptoms suggestive of deficiency (anaemia, neuropathy, cognitive changes) Long-term metformin use (MHRA 2022 guidance advises monitoring) Long-term proton pump inhibitor use Vegetarian or vegan diets Conditions affecting absorption (pernicious anaemia, coeliac disease, gastric surgery) Advanced liver disease (NASH, fibrosis, or cirrhosis) Monitoring frequency should be individualised based on disease severity and risk factors
